Fleroxacin-d3 Internal Standard Protocol for LC-MS/MS Quantification

Fleroxacin-d3 is a trideuterium-labeled stable-isotope internal standard designed for accurate, interference-free quantification of the fluoroquinolone antibiotic fleroxacin in biological and environmental matrices by LC-MS/MS.

Product Name

Fleroxacin-d3

SKU

F1539420

Isotope Labeling

Trideuterium (d3); three hydrogen atoms replaced by deuterium

Primary Application

Stable-isotope dilution LC-MS/MS internal standard for fleroxacin quantification

Reference Supplier Code

PT42204 (谱同生物)

Compound Class

Deuterium-labeled fluoroquinolone antibiotic

Principle and Rationale

Fleroxacin-d3 serves as a stable-isotope-labeled (SIL) internal standard for the quantitative bioanalysis of fleroxacin, a broad-spectrum fluoroquinolone antibiotic. Because the deuterium-labeled analog is chemically near-identical to the unlabeled analyte, it undergoes the same extraction recovery, chromatographic retention, and ionization behavior during LC-MS/MS analysis. The three-mass-unit shift (d3) between the internal standard and the native compound allows unambiguous differentiation in the mass spectrometer via selected reaction monitoring (SRM) or multiple reaction monitoring (MRM), eliminating matrix-effect errors and improving assay precision and accuracy.

Stable-isotope dilution (SID) methodology using Fleroxacin-d3 is the gold standard approach recommended for regulated bioanalytical methods subject to FDA/EMA guidelines for method validation.

Stock Solution Preparation

Materials required: Fleroxacin-d3 (SKU F1539420), DMSO (analytical grade) or acetonitrile (LC-MS grade), amber glass vials, analytical balance, volumetric pipettes.

1. Allow the vial of Fleroxacin-d3 to equilibrate to room temperature for at least 15 minutes before opening to prevent condensation on the compound.
2. Prepare a primary stock solution at a nominal concentration of 1.0 mg/mL in DMSO or acetonitrile (LC-MS grade). Accurately weigh the compound or use the certificate of analysis (CoA) certified mass to calculate the exact volume of solvent required.
3. Vortex gently for 30–60 seconds until completely dissolved. Visually confirm clarity of the solution.
4. Aliquot the stock solution into single-use amber microcentrifuge tubes (e.g., 50–100 µL per aliquot) to minimize freeze–thaw cycles.
5. Store aliquots at −20 °C or −80 °C protected from light. Label each vial with compound name, concentration, solvent, date of preparation, and operator initials.

Note: Avoid repeated freeze–thaw cycles, as these may compromise isotopic integrity and concentration accuracy.

LC-MS/MS Method Setup and Internal Standard Spiking

Working solution preparation: Dilute the primary stock solution in LC-MS grade acetonitrile/water (50:50, v/v) to prepare a working internal standard (IS) solution at 100–500 ng/mL. The exact working concentration should be optimized based on the expected analyte range and instrument sensitivity.

Sample spiking procedure:

1. Add a fixed volume of the IS working solution (typically 10 µL) to each study sample, calibration standard, and quality control (QC) sample before protein precipitation or liquid–liquid extraction.
2. Vortex briefly to ensure uniform mixing.
3. Proceed with the sample preparation workflow (protein precipitation with acetonitrile, liquid–liquid extraction, or solid-phase extraction) as applicable.
4. After extraction, evaporate the organic layer under a gentle nitrogen stream at 40 °C, reconstitute in mobile phase, and transfer to LC-MS vials.

Suggested LC conditions: Reversed-phase C18 column; mobile phase A: 0.1% formic acid in water; mobile phase B: 0.1% formic acid in acetonitrile; gradient elution 5–95% B over 8 minutes; column temperature 40 °C; injection volume 5–10 µL.

Suggested MS conditions (MRM): Positive electrospray ionization (ESI+). Monitor the appropriate precursor-to-product ion transitions for both fleroxacin and Fleroxacin-d3. Confirm MRM transitions from authentic reference standards and the compound's CoA prior to study sample analysis.

Note: Specific MRM transitions, collision energies, and instrument source parameters must be optimized on the specific instrument used. Flag for instrument-specific optimization.

Data Processing and Calibration

Calculate the peak area ratio (PAR) of fleroxacin to Fleroxacin-d3 for each sample. Construct a calibration curve by plotting PAR against nominal fleroxacin concentration using a weighted linear or quadratic regression (1/x or 1/x² weighting is typical for bioanalytical assays).

Acceptance criteria (typical regulated bioanalysis):

• Calibration curve r² ≥ 0.99
• Back-calculated concentrations of calibration standards within ±15% of nominal (±20% at LLOQ)
• QC accuracy within ±15% of nominal; precision (CV%) ≤15% (≤20% at LLOQ)
• IS response consistency: flag any sample where IS peak area deviates >30% from the mean IS response of the batch

These acceptance criteria are derived from general bioanalytical guidance principles (e.g., FDA Bioanalytical Method Validation Guidance, 2018; EMA guideline). Verify applicability to your specific regulatory context.

Storage, Handling, and Safety

Storage: Store Fleroxacin-d3 (SKU F1539420) as received, at −20 °C, protected from light and moisture. Do not store in frost-free freezers that undergo temperature cycling. Check the product CoA and Safety Data Sheet (SDS) for lot-specific storage instructions.

Handling precautions:

• Handle in a well-ventilated area or chemical fume hood when weighing or preparing solutions.
• Wear appropriate personal protective equipment (PPE): nitrile gloves, lab coat, and safety glasses.
• Fleroxacin is a fluoroquinolone antibiotic; avoid unnecessary exposure. Dispose of waste according to institutional and local regulations.
• Deuterium-labeled compounds are non-radioactive; standard chemical laboratory safety practices apply.

Stability: Specific stability data for Fleroxacin-d3 stock solutions and working solutions should be established during method validation. As a general guideline, stock solutions in DMSO or acetonitrile stored at −20 °C are expected to be stable for several months when properly aliquoted and protected from light; however, validated stability data should be generated and referenced.

Flag: Specific stability duration data for this product are not available in the source material and must be validated experimentally or sourced from the CoA.

Frequently asked questions

What is Fleroxacin-d3 and why is it used as an internal standard?

Fleroxacin-d3 is a stable-isotope-labeled analog of the fluoroquinolone antibiotic fleroxacin, in which three hydrogen atoms are replaced by deuterium atoms. It is used as an internal standard in LC-MS/MS assays because it is chemically and chromatographically nearly identical to fleroxacin, yet distinguishable by a 3 Da mass shift in the mass spectrometer. This allows correction for variability in sample preparation, extraction recovery, and matrix-induced ionization suppression, yielding more accurate and precise quantitative results.

Which solvents are recommended for preparing Fleroxacin-d3 stock solutions?

DMSO (analytical grade) or LC-MS grade acetonitrile are the recommended solvents for preparing primary stock solutions of Fleroxacin-d3. The choice of solvent should be compatible with your downstream assay and matrix. DMSO offers good solubility for many fluoroquinolones, while acetonitrile is preferred when direct injection compatibility with the LC mobile phase is required. Always verify complete dissolution visually before use.

How should Fleroxacin-d3 be stored to maintain its integrity?

Fleroxacin-d3 should be stored at −20 °C, protected from light and moisture, in tightly sealed amber vials. Stock solutions should be aliquoted to minimize freeze–thaw cycles, which can degrade the compound and introduce concentration errors. Avoid storing in frost-free freezers that undergo temperature fluctuations. Always consult the product Certificate of Analysis (CoA) and Safety Data Sheet (SDS) for lot-specific recommendations.

Is Fleroxacin-d3 radioactive or hazardous?

Fleroxacin-d3 is not radioactive. Deuterium is a stable, non-radioactive isotope of hydrogen. Standard laboratory chemical safety practices apply, including the use of gloves, lab coat, and eye protection. As a fluoroquinolone antibiotic analog, unnecessary skin contact or inhalation should be avoided. Dispose of all waste in accordance with institutional and local environmental regulations.

What MRM transitions should I use for Fleroxacin-d3 in LC-MS/MS?

Specific MRM transitions (precursor ion, product ion, collision energy, and source parameters) for Fleroxacin-d3 must be optimized empirically on your specific mass spectrometer model and configuration. As a starting point, the precursor ion of Fleroxacin-d3 in ESI+ mode will be 3 Da higher than that of unlabeled fleroxacin. Consult the product CoA and published literature for guidance, and always perform instrument-specific tuning before sample analysis.

References

1. U.S. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. FDA, 2018.
2. European Medicines Agency. Guideline on Bioanalytical Method Validation. EMA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2, 2011.
3. Wieling J. LC-MS-MS experiences with internal standards. Chromatographia. 2002;55(S1):S107–S113.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.